Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393468 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03393468 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 16 participants.
The verdict
NCT03393468, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics of dapivirine gel administered rectally to HIV-1 seronegative adults.
Interventions
- DRUG Dapivirine gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393468
The ClinicalTrials.gov registry entry for NCT03393468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dapivirine gel is the first listed.
NCT03393468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03393468 about?
NCT03393468 is a clinical study titled "Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults". The purpose of this study is to evaluate the pharmacokinetics of dapivirine gel administered rectally to HIV-1 seronegative adults.
What is the current status of trial NCT03393468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-05-10. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03393468?
The interventions under investigation include: Dapivirine gel (DRUG).
Who is sponsoring clinical trial NCT03393468?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.